A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.

The BELLA phase 2 clinical trial of relacorilant plus nab-paclitaxel and Avastin among patients with platinum-resistant ...

The ROSELLA trial showed relacorilant plus nab-paclitaxel improved progression-free survival in platinum-resistant ovarian cancer patients. Relacorilant reduced disease progression risk by 30% and ...

According to Corcept Therapeutics, the results from the ROSELLA trial will be used to support a New Drug Application for relacorilant in platinum-resistant ovarian cancer. The Company expects to ...

Complete results from ROSELLA will be presented at a medical conference this year. Results from Corcept’s Phase 2 trial of relacorilant in patients with platinum-resistant ovarian cancer were ...

Corcept’s ROSELLA Phase 3 trial of relacorilant plus nab-paclitaxel reduced disease progression risk by 30% in ovarian cancer. Relacorilant patients had a median overall survival of 16.0 months ...

With positive data from the phase 3 ROSELLA study using relacorilant + nab-paclitaxel for the treatment of patients with platinum-resistant ovarian cancer, plus three other expected catalysts in ...

Corcept Therapeutics shares nearly doubled in premarket trading Monday after the company said it received positive data from its phase 3 ovarian cancer treatment trial. Shares rose 93% ahead of the ...